In this article, we will be taking a look at the 10 Best Biotech Stocks Under $10 to Buy.
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years. The start of this year has been more muted, despite the great performance from the previous year. However, he did note that earlier in the year, there had been a similar trend, with momentum growing. Today, there is still a lot of underground activity, including mergers and acquisitions for more than $225 billion, which has contributed to stable prices. According to Casdin, investors are currently searching for the next big opportunity while in an experimental phase.
There is a lot of hope for the future due to a significant change in the industry: by 2030, almost $200 billion in pharmaceutical revenue is anticipated to face patent expirations. Large pharmaceutical companies are under pressure to reinvest and rebuild their pipelines due to the availability of over a trillion dollars in funding, which encourages more dealmaking. Casdin also emphasized the importance of artificial intelligence, stressing that although it can speed up invention and change procedures, it cannot take the place of the biological and physical aspects of medication development. Rather, AI serves as a potent instrument that promotes innovation and increases productivity.
Investors are also paying more attention to the larger healthcare industry. After a period of underperformance due to policy concerns, it has been outperforming since the beginning of the year alongside normally protective sectors. Because healthcare is less correlated with technology and sentiment is improving, analysts predict continued upside.
This outlook is further supported by industry trends. As businesses increase their purchases in response to impending patent cliffs, biopharma is starting the year with newfound vigor. Smaller biotech companies with promising pipelines are also seeing an increase in investor confidence. Furthermore, the convergence of digital health and biotechnology is drawing additional investment, setting the industry up for long term growth and potential.
With that said, let’s view the best biotech stocks.
Our Methodology
For our methodology, we began by screening for stocks with a closing price under $10 as of April 10 and positive upside potential. From the filtered results, we selected stocks with the most recent news and developments, and then ranked them in ascending order based on the total number of hedge fund holders as of Q4 2025, as tracked by the Insider Monkey database.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Here is our list of the 10 best biotech stocks under $10 to buy.
10. MacroGenics, Inc. (NASDAQ:MGNX)
Number of Hedge Fund Holders: 15
Stock Price as of Last Close on April 10: $3.60
MacroGenics, Inc. (NASDAQ:MGNX) is one of the best biotech stocks.
TheFly reported on April 10 that B. Riley raised its rating on MGNX to Buy from Neutral and assigned a $9 price target. The firm highlighted the company’s positioning in the evolving antibody-drug conjugate landscape, particularly within the ADAM9 TOPO1 inhibitor segment. Its view follows recent industry developments, including a notable transaction involving Gilead, which prompted a reassessment of valuation approaches for next-generation ADC platform companies.
Separately, on April 8, MacroGenics, Inc. (NASDAQ:MGNX) announced that the U.S. Food and Drug Administration lifted the partial clinical hold on its Phase 2 LINNET trial evaluating lorigerlimab, an investigational bispecific antibody targeting PD-1 and CTLA-4. During the restriction period, patients already enrolled were permitted to continue treatment.
With the hold now removed, the company plans to restart enrollment of new participants under an updated study protocol that incorporates added safety measures to address potential blood-related and cardiac risks. The company indicated that it worked closely with regulators to resolve concerns and remains on schedule to provide a clinical update on the program later in the year, as development of the therapy continues.
MacroGenics, Inc. (NASDAQ:MGNX) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for cancer. It leverages proprietary technologies to create targeted treatments designed to enhance immune response and improve outcomes for patients with unmet medical needs.
9. Karyopharm Therapeutics Inc. (NASDAQ:KPTI)
Number of Hedge Fund Holders: 21
Stock Price as of Last Close on April 10: $8.00
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is one of the best biotech stocks on this list.
TheFly reported on April 7 that RBC Capital reduced its price target on KPTI to $16 from $23 while maintaining an Outperform rating. The revision was part of a broader biotech sector preview ahead of first-quarter results. The firm noted potential short-term pressures from seasonal dynamics, reimbursement resets, fewer selling days, and weather-related disruptions, particularly affecting newly launched and clinic-administered products. Despite these challenges, it highlighted that renewed merger and acquisition activity, along with improved visibility on pricing and tariff-related factors, could help support sentiment and offset broader macroeconomic uncertainty within the sector.
Moreover, earlier on March 24, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) entered into a securities purchase agreement with RA Capital Management for a private financing expected to generate approximately $30 million in gross proceeds, with potential for additional funds if associated warrants are exercised.
The transaction includes the sale of common stock, pre-funded warrants, and accompanying warrants, with closing anticipated later in the month, subject to customary conditions. The company plans to use the proceeds to support general corporate activities, including advancing its clinical development programs. Combined with existing resources, the funding is expected to sustain operations into the third quarter of 2026.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel cancer therapies. It specializes in selective inhibitors of nuclear export (SINE) to treat hematologic malignancies and solid tumors.
8. MeiraGTx Holdings plc (NASDAQ:MGTX)
Number of Hedge Fund Holders: 23
Stock Price as of Last Close on April 10: $8.97
MeiraGTx Holdings plc (NASDAQ:MGTX) is one of the best biotech stocks to invest in.
TheFly reported on April 1 that Evercore ISI analyst Gavin Clark-Gartner reduced the price target on MGTX from $20 to $18 while maintaining an Outperform rating. The revision was part of a broader update across small- and mid-cap biotechnology companies tied to an assessment of upcoming second-quarter catalysts. The firm also considered longer-term developments, noting that stock performance in the sector is increasingly influenced by expectations around full-year 2026 milestones.
Earlier on March 26, MeiraGTx Holdings plc (NASDAQ:MGTX) announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its AAV2-hAQP1 program for treating Grade 2 and Grade 3 late xerostomia resulting from radiotherapy in cancers of the upper aerodigestive tract.
The designation was supported by long-term data from a Phase 1 dose-escalation study demonstrating sustained outcomes. The therapy had previously received Regenerative Medicine Advanced Therapy status, further strengthening its regulatory position. The company is advancing a Phase 2 study designed to support a potential biologics license application, with data expected following completion of patient treatment and follow-up, keeping the program on track for future regulatory submission and commercialization plans.
MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage biotechnology company focused on developing gene therapies for serious diseases. It leverages viral vector technologies to target genetic disorders, ocular diseases, and neurodegenerative conditions with the aim of delivering durable, transformative treatments.
7. Bicycle Therapeutics plc (NASDAQ:BCYC)
Number of Hedge Fund Holders: 23
Stock Price as of Last Close on April 10: $4.94
Bicycle Therapeutics plc (NASDAQ:BCYC) is one of the best biotech stocks on this list.
TheFly reported on April 8 that Morgan Stanley reduced its price target on BCYC to $12 from $13 while maintaining an Equal Weight rating. The firm updated its valuation model following the company’s decision to refocus its pipeline strategy toward BT5528 and next-generation Bicycle conjugate programs. The revision also incorporates recent organizational changes, including a workforce reduction of approximately 30%.
Separately, earlier on March 17, Bicycle Therapeutics plc (NASDAQ:BCYC) also released its fourth-quarter and full-year 2025 results along with a broader corporate update. The company reported cash and cash equivalents of $628.1 million as of December 31, 2025, down from $879.5 million a year earlier, mainly due to operational cash usage. Collaboration revenue rose to $48.0 million for Q4 and $72.6 million for the full year, compared with $3.7 million and $35.3 million in the prior-year periods, driven by revenue recognition from terminated partnership agreements.
The corporation’s R&D expenses increased to $240.3 million for the year, reflecting higher clinical program activity, personnel costs, and restructuring-related charges, while G&A expenses rose to $79.4 million due to higher compensation and share-based payments. Net loss widened to $219.0 million for 2025 compared with $169.0 million in 2024. Alongside results, the company highlighted pipeline progress, strategic reprioritization, and ongoing clinical and preclinical development across its oncology programs.
Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing novel therapies using its proprietary bicyclic peptide technology. It focuses on targeted treatments for cancer and other serious diseases by designing precision medicines that bind selectively to disease-related proteins.
6. Arbutus Biopharma Corporation (NASDAQ:ABUS)
Number of Hedge Fund Holders: 27
Stock Price as of Last Close on April 10: $4.15
Arbutus Biopharma Corporation (NASDAQ:ABUS) is among the best biotech stocks under $10 to buy.
TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $7.00 to $5.50 while maintaining a Buy rating. The revision was driven by updated expectations around the outcome of Moderna’s appeal in ongoing litigation, which could influence a potential $1.3 billion payment tied to the case. The firm adjusted its probability assessment, increasing the likelihood of a Moderna win on appeal, which in turn reduced its valuation outlook for ABUS.
On March 23, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported its fourth-quarter and full-year 2025 financial results and provided a corporate update. The company highlighted its ongoing litigation-related developments, including a settlement agreement with Moderna and Genevant under which ABUS is entitled to a portion of a $950 million upfront payment expected in July 2026, along with potential eligibility for an additional $1.3 billion contingent on an appellate outcome.
It also noted continued legal proceedings involving its lipid nanoparticle intellectual property. For the year, the business reported revenue of $14.1 million, net loss of $33.5 million, cash and investments of $91.5 million, and reduced operating expenses driven by restructuring and cost optimization efforts focused on its clinical pipeline.
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases. It is particularly known for its work in hepatitis B treatments, using RNA interference and lipid nanoparticle delivery technologies to target and suppress viral replication.
While we acknowledge the potential of ABUS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABUS and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Biotech Stocks Under $10 to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
